New drug cocktail offers hope for Hard-to-Treat ovarian cancer
NCT ID NCT07591831
First seen May 19, 2026 · Last updated May 22, 2026 · Updated 1 time
Summary
This study tests a combination of two drugs (liposomal irinotecan and enlonstobart) in 30 women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this treatment can shrink tumors or slow the disease. Participants will receive the drugs every two weeks and have scans every eight weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.